Fig. 5: DLD targeting therapy in myeloma in vitro.
From: Dihydrolipoamide dehydrogenase (DLD) is a novel molecular target of bortezomib
A The time and concentration dependence of CPI-613 in MM cell lines (ARD and AMO.1) was detected by CCK-8 (CPI-613 25 μM, 50 μM, 100 μM, 150 μM, and 200 μM, p < 0.05). B After treating AMO.1 or ARD cells with BTZ monotherapy, CPI-613 monotherapy, or both drugs simultaneously, the proteasome activity of the cells was detected. The results showed that the proteasome activity of BTZ monotherapy and CPI-613 monotherapy groups both decreased and the group treated with BTZ combined with CPI-613 showed the greatest decrease in proteasome activity (p < 0.05). C ARD cells were treated with CPI-613 and various concentrations of BTZ (alone or in combination). CCK-8 was used to detect cell viability (as shown in the left figure, p < 0.05), and cell apoptosis was detected by flow cytometry with an apoptosis assay kit (as shown in the right figure, p < 0.05). D The three-dimensional synergy diagram of CPI-613 and BTZ was shown in the figure, and the synergistic score (11.775) of CPI-613 and BTZ in ARD cells was calculated by SynergyFinder based on the data shown in (C), *p < 0.05.
